



Advanced Cell Technology



Corporate Presentation
March 2010



Cautionary Statement Concerning Forward-Looking Statements

This presentation is intended to present a summary of ACT's ("ACT", or "Advanced Cell Technology Inc", or "the Company") salient business characteristics.

The information herein contains "forward-looking statements" as defined under the federal securities laws. Actual results could vary materially. Factors that could cause actual results to vary materially are described in our filings with the Securities and Exchange Commission.

You should pay particular attention to the "risk factors" contained in documents we file from time to time with the Securities and Exchange Commission. The risks identified therein, as well as others not identified by the Company, could cause the Company's actual results to differ materially from those expressed in any forward-looking statements.

ACT Therapeutics

| ACT Proprietary Human Therapeutic Programs | Treatment | Clinical Stage |
|---|--|---|
| Blastomere Program | Development of embryonic stem cell lines without destruction of embryo | Pre-Clinical |
| Retinal Pigment Epithelium (RPE) Program | Treatment of Age-related Macular Degeneration (AMD) and Retinal Degenerative Diseases | Clinical IND awaiting FDA approval |
| Myoblast Program | Treatment of Heart Disease, Heart Attack and Heart Failure | Phase II |
| Hemangioblast program | Treatment of Diseases and Disorders of the Circulatory and Vascular Systems | Pre-Clinical |

Intellectual Property Protection

| Composition of Matter Patent | Status |
|---|---------|
| Muscle cells | Awarded |
| Stem cells capable of forming nerve or muscle cells | Awarded |
| Media for preservation and transplant of muscle cells | Awarded |

| Use Patents | Status |
|--|---------|
| Catheter delivery of cells | Pending |
| Combinations of myoblasts and stem cells | Pending |
| Combinations of myoblasts and muscle survival factors | Pending |
| Multiple next generation technologies complementary to existing patents and claims | Pending |
| Multiple use patents for heart disease | Pending |

ACT owns or licenses over 150 patents and patent applications related to stem cell and regenerative therapies

Institutional Collaborators



Memorial Sloan-Kettering
Cancer Center



Advanced Cell's Institutional Collaborators include:

Casey Eye Institute

Moran Eye Institute

Harvard

Stanford

University of Florida

University of Illinois

Colorado State University

Mayo Clinic

UCSF


Johns Hopkins

Sloan Kettering

University of Iowa

U.C. Berkeley

Blastomere Program: Synthesizing Stem Cells without Harm to the Embryo




- Company scientists successfully generate stem cell lines without destruction of embryo
- Cell lines retain potential to form all cells in the human body
- Potential to treat a range of human diseases
- Technology has been reproduced and peer-reviewed on several occasions
- National Institute of Health (NIH) proposing expanded funding regulations to accommodate ACT's lines

First Proven Alternative hESC Method



- Enables Derivation of New hESC Lines via Pre-implantation Genetic Diagnosis (PGD) Method, Preserving Development Potential of the Embryo



**Hemangioblasts
Differentiated from
Blastomere hESC Lines**

- 7 hESC lines awaiting NIH approval for funding
- Technology is used to develop RPE cells for our clinical trials for Stargardt's disease



RPE Program: Why RPE?

- Pigmented epithelium cells are easy to identify
- Small dosage vs. other therapies
- The eye is an immune-privileged site, thus no risk of rejection at the injection site

- Ease of administration



- Doesn't require a separate approval by the FDA (universal applicator)
- Procedure is already used by eye surgeons; no new skill set required for doctors

- RPE cell therapy may positively impact over 200 retinal diseases

RPE Program Status

| | |
|--------------------------------|--|
| 2006 | Developed the “Proof of Concept” for ACT’s RPE cells in RCS animal model |
| 2008 | Pre – IND meeting with FDA |
| 2009 | Filed IND for Stargardt’s disease |
| 2010 – 3 rd Quarter | FDA approval |
| 2010 – 4 th Quarter | Complete Stage 1 of Phase I Clinical Trial for Stargardt’s disease |

GMP-compliant Human RPE Cells Derived from Embryonic Stem Cell Lines Rescue Visual Function In a Rat Model for Photoreceptor Degeneration



“Our results show that a well-characterized GMP-compliant embryonic stem cell-derived RPE cells can survive after transplantation to the sub-retinal space of RCS rats, integrate into host RPE layer without migration into the retina and continue to express at least some of the molecules characteristic of RPE. The cells are effective in rescuing photoreceptors from degeneration and result in significant rescue of visual function over sham-operated animals for the long term.”

Myoblast Program Highlights

Target Market for Myoblast Program

Sufferers of Heart Failure, Chronic Heart Failure and patients with scarred or ischemic (dead) heart tissue caused by or related to heart attack

Program Status

Clearance from FDA to Proceed with Phase II Clinical Trials in the U.S.



Myoblast Program: Clinical Trial Summary

| | Phase 1 LVAD | Phase 1 CABG | Phase 1b CABG | Phase 1b Catheter |
|---------------------|--|---|--|--|
| Patients | 6 patients | 12 patients | 12 patients | 23 Patients (12 treated, 11 control) |
| Indication | LVAD Bridge to Transplant | +CABG | +CABG | Catheter Injection |
| Dose | Single Dose - 300 MM Cells | Escalating - 10, 30, 100 and 300 MM Cells | Single Dose - 300 MM Cells | Escalating - 30, 100, 300 and 600 MM Cells |
| Primary Endpoint | Safety | Safety | Safety | Safety |
| Result | Demonstrated cell survival in humans | Dose escalation, Safe at all doses | Survival of cells (cardiac imaging), improved symptoms and function | Safe at all doses, improved symptoms and function |

Myoblast Program: Phase II Clinical Trial

- **80 total patients (1:1 treatment vs. control)**
- **Double-blind, placebo-controlled (sham procedure)**
- **Catheter delivery of cells: percutaneous targeted delivery**
- **Three-month, six-month, and 12-month follow-up**
- **Endpoints: Improvement in HF symptoms and Ventricular Volumes**
- **Primary endpoint: Improvement in heart failure symptoms measured by “Kansas City Cardiomyopathy Questionnaire”**
- **Supporting endpoints: Ventricular volumes, Six minute walk test**
- **Interim data analysis at six-months by Independent Review Board**

Hemangioblast Program: Partnership





- Joint Venture with leading Korean stem cell developer CHA Biotech Co.
- The J.V., 'Stem Cell & Regenerative Medicine International', is focused on the development of human blood cells and related products




Hemangioblast Program: Overview

The HG cell is the precursor to all cell types in the circulatory and vascular systems



Hemangioblast Program: Synthesizing Blood Cells



The ACT Therapeutic Timeline

| Timetable for Therapeutic Program Milestones | Period |
|---|---------------------------------|
| Completion of end of life tumorigenicity & biodistribution studies for RPE | Q1 2010 |
| Received Orphan indication from Department of Health and Human Services | Q1 2010 |
| Receive FDA clearance to commence with Phase I Clinical Trials | Q3 2010 |
| Treat 1st Patient in history with a hECS-based therapy | Q3 2010 |
| 1st Quadrant Safety Data on Treated Patients | Q4 2010 |
| File 2nd Phase I IND for another Retinal Disease | 2nd half 2010 |
| Announce 2nd cellular-based IND in area other than retinal program | 2nd half 2010 |

The Advanced Cell Technology Team

World Class Scientific Team lead by

Dr. Robert Lanza, M.D. – Chief Scientific Officer

Dr. Jonathan Dinsmore, PhD – Myoblast Project Advisor

Matthew Vincent, PhD – IP / Licensing Advisor

Seasoned Management Team:

William Caldwell IV – Chief Executive Officer


Edmund Mickunas – Vice President of Regulatory

Roger Gay, PhD – Senior Director of Manufacturing


Rita Parker – Director of Operations

State of the Company

- Two years of cash available
- Phase I/II trial fully funded
- Anticipating cell lines will qualify for federal funding
- Actively pursuing development partners offshore to accelerate development of programs



ADVANCED **CELL** TECHNOLOGY



Thank you for your time

For more information, visit www.advancedcell.com

Advanced Cell Technology is traded on the OTC BB, symbol: ACTC